2018 IPO

Sutro Biopharma Stock

Develops protein therapeutics by using OCFS protein synthesis technology

Sign up today and learn more about Sutro Biopharma Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Sutro Biopharma Stock

Sutro Biopharma is a biopharmaceutical company that uses its patented OCFS protein synthesis technology to develop next-generation protein therapeutics for the treatment of human disease. Sutro is applying its technology to the development of next-generation, non-native protein structures such as antibody fragments, single-chain antibodies, and other proteins with novel scaffolds. We are also working to provide novel functionalities to our core technology with a goal of further improving the therapeutic benefit of the products we make. Sutro Biopharma, Inc. has a 24,000 sq. ft facility located in South San Francisco, California. Our pilot facility houses 15-Liter fermentors, a 200-L fermentor, and related research, development and downstream activities to support the scale-up of protein therapeutic candidates.

Funding History

January 2006$1.0M
October 2007$305K
December 2007$21.0M
March 2009$15.0M
November 2010$36.5M
May 2012$16.5M
December 2013$26.0M
July 2018$85.4M

Management

Founder & Director

James R. Swartz

Vice President of Development and Manufacturing

Henry Heinsohn

Vice President of Research

Aaron Sato

Senior Director, Supply Chain and CMC Team Lead

Heidi Hoffmann

Chief Business Officer

Jeremy Bender

Chief Executive Officer, Board of Directors

William J. Newell

Chief Scientific Officer

Trevor Hallam

Chief Financial Officer

Edward Albini

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo